Form 4 for STLN Starling Oncology, Inc.
Accepted 2024-11-21 00:00:00 ET · period of report 2024-11-20 · accession 0001799191-24-000042 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-21 | 2024-11-20 | STLN | Carter Robert Ross | CFO | D - Sale to Iss | $0.14 | -235 | 31.8K | -0.7% | -$32.90 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-11-20 | D | D | 235 | $0.14 | 31,759 | D | — | — | (F1) The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. (F2) Price is the volume weighted average selling price of all sales by the Reporting Person on November 20, 2024 within a one-dollar range. Actual prices ranged from $0.136 to $0.168. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |